Correspondence 0001104659-24-005230 from BioXcel Therapeutics, Inc. (BTAI) (CIK 0001720893) (BTAI)
BioXcel Therapeutics, Inc. (BTAI) (CIK 0001720893)
Date: Jan. 19, 2024 · CIK: 0001720893 · Accession: 0001104659-24-005230
AI Filing Summary & Sentiment
File numbers found in text: 333-276488
Letter
BioXcel Therapeutics, Inc.
555 Long Wharf Drive
New Haven, CT 06511
January 19, 2024
Via EDGAR
Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, DC 20549
Attention: Cindy Polynice
Re: BioXcel Therapeutics, Inc.
Registration Statement on Form S-3 Filed January 12, 2024
File No. 333-276488
To the addressee set forth above:
Pursuant to Rule 461(a) under the Securities Act of 1933, as amended, BioXcel Therapeutics, Inc. (the “Company”) hereby respectfully requests that the effective date of the Company’s Registration Statement on Form S-3 (File No. 333-276488) be accelerated by the Securities and Exchange Commission to 4:30 p.m. Washington D.C. time on January 22, 2024 or as soon as practicable thereafter.
The Company requests that we be notified of such effectiveness by a telephone call to Peter N. Handrinos of Latham & Watkins LLP at (617) 948-6060 or Keith L. Halverstam of Latham & Watkins LLP at (212) 906-1761 and that such effectiveness also be confirmed in writing.
Sincerely,
BioXcel Therapeutics, Inc.
Show Raw Text
CORRESP
1
filename1.htm
BioXcel Therapeutics, Inc.
555 Long Wharf Drive
New Haven, CT 06511
January 19, 2024
Via EDGAR
Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, DC 20549
Attention: Cindy Polynice
Re:
BioXcel Therapeutics, Inc.
Registration Statement on Form S-3 Filed January 12, 2024
File No. 333-276488
To the addressee set forth above:
Pursuant to Rule 461(a) under the Securities Act
of 1933, as amended, BioXcel Therapeutics, Inc. (the “Company”) hereby respectfully requests that the effective
date of the Company’s Registration Statement on Form S-3 (File No. 333-276488) be accelerated by the Securities and Exchange Commission
to 4:30 p.m. Washington D.C. time on January 22, 2024 or as soon as practicable thereafter.
The Company requests that we be notified of such
effectiveness by a telephone call to Peter N. Handrinos of Latham & Watkins LLP at (617) 948-6060 or Keith L. Halverstam of Latham
& Watkins LLP at (212) 906-1761 and that such effectiveness also be confirmed in writing.
Sincerely,
BioXcel Therapeutics, Inc.
By:
/s/ Richard Steinhart
Richard Steinhart
Chief Financial Officer
cc:
Peter N. Handrinos, Latham & Watkins LLP
Keith L. Halverstam, Latham & Watkins LLP
N. Danny Shulman, Latham & Watkins LLP
Gregory M. Drozdzal, Latham & Watkins LLP